The renin-angiotensin-aldosterone system: A specific target for hypertension management

American Journal of Hypertension

Volumn 12, Issue 12 SUPPL. 1, 1999, Pages

  Weir, Matthew R ^a   Dzau, Victor J ^b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b NONE

Author keywords

Angiotensin II; Function; Structure; Type 1 receptor; Type 2 receptor

Indexed keywords

ADENYLATE CYCLASE; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CATHEPSIN G; CHYMASE; COLLAGEN; COMPLEMENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; INOSITOL TRISPHOSPHATE; LIPID; LIPOPROTEIN; PHOSPHOLIPASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C; RECEPTOR; RENIN; SODIUM; SODIUM CHLORIDE; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA1; VASOPRESSIN; WATER;

ADRENAL CORTEX; ADRENERGIC SYSTEM; ATHEROSCLEROSIS; BINDING SITE; BLOOD PRESSURE; CLINICAL TRIAL; EXTRACELLULAR MATRIX; HEART MUSCLE CONTRACTILITY; HEART RATE; HUMAN; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; HYPERTENSION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; SYMPATHETIC NERVOUS SYSTEM; VASOCONSTRICTION;

EID: 0033398149     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(99)00103-x     Document Type: Article

References (69)

1. Bolli P, Fernandez PG, Bühler FR: Beta-blockers in the treatment of hypertension, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management, Vol. 2. Raven Press, New York, 1990, p 2181.
2. Sealey JE, Laragh JH: The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management, Vol. 1. Raven Press, New York, 1990, p 1287.
3. Timmermans PB, Wong PC, Chiu AT, et al: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-251.
4. Weir MR: Angiotensin-II receptor antagonists: a new class of antihypertensive agents. Am Fam Physician 1996;53:589-594.
5. Dzau VJ: Evolving concepts of the renin-angiotensin system. Focus on renal and vascular mechanisms. Am J Hypertens 1988;1:334S-337S.
6. Gibbons GH: Autocrine-paracrine factors and vascular remodeling in hypertension. Curr Opin Nephrol Hypertens 1993;2:291-298.
7. Gibbons GH, Dzau VJ: The emerging concept of vascular remodeling. N Engl J Med 1994; 330:1431-1438.
8. Dzau VJ, Sasamura H, Hein L: Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens 1993;11(suppl):S13-18.
9. Hall JE, Gayton AC: Control of sodium excretion and arterial pressure by intrarenal mechanisms and the renin-angiotensin system, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management, Vol. 1. Raven Press, New York, 1990, p 1105.
10. Hall JE: Control of sodium excretion by angiotensin II: intrarenal mechanisms and blood pressure regulation. Am J Physiol 1986;250:R960-972.
11. Bernstein KE, Berk BC: The biology of angiotensin II receptors. Am J Kidney Dis 1993;22:745-754.
12. Smith RD, Timmermans PB: Human angiotensin receptor subtypes. Curr Opin Nephrol Hypertens 1994;3: 112-122.
13. Timmermans PB, Smith RD: Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur Heart J 1994;15(suppl D):79-87.
14. Griendling KK, Rittenhouse SE, Brock TA, et al: Sustained diacylglycerol formation from inositol phospholipids in angiotensin II-stimulated vascular smooth muscle cells. J Biol Chem 1986;2615901-5906.
15. Brock TA, Alexander RW, Ekstein LS, et al: Angiotensin increases cytosolic free calcium in cultured vascular smooth muscle cells. Hypertension 1985;7:I105-109.
16. Griendling KK, Tsuda T, Berk BC, Alexander RW: Angiotensin II stimulation of vascular smooth muscle. J Cardiovasc Pharmacol 1989;14:S27-33.
17. 2+ mobilization and protein kinase C activation. J Biol Chem 1989;264:526-530.
18. Naftilan AJ, Pratt RE, Dzau VJ: Induction of plateletderived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1419-1424.
19. Geisterfer AA, Peach MJ, Owens GK: Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988;62:749-756.
20. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM: Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450-456.
21. Noble NA, Border WA: Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target? Semin Nephrol 1997;17:455-466.
22. Kagami S, Kuhara T, Okada K, et al: Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 1997;51:664-671.
23. Pratt RE: Regulation of vascular smooth-muscle cell growth by angiotensin II. Blood Press 1996;2(suppl): 6-9.
24. Griendling KK, Murphy TJ, Alexander RW: Molecular biology of the renin-angiotensin system. Circulation 1993;87:1816-1828.
25. Dzau VJ, Gibbons GH, Pratt RE: Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 1991;18:II100-105.
26. Feener EP, Northrup JM, Aiello LP, King GL: Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995;95:1353-1362.
27. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995;95:995-1001.
28. 1 angiotensin receptors. Am J Hypertens 1992;5:236S-242S.
29. Gasc JM, Shanmugam S, Sibony M, Corvol P: Tissue-specific expression of type 1 angiotensin II receptor subtypes. An in situ hybridization study. Hypertension 1994;24:531-537.
30. Burson JM, Aguilera G, Gross KW, Sigmund CD: Differential expression of angiotensin receptor 1A and IB in mouse. Am J Physiol 1994;267:E260-267.
31. Llorens-Cortes C, Greenberg B, Huang H, Corvol P: Tissular expression and regulation of type 1 angiotensin II receptor subtypes by quantitative reverse transcriptase-polymerase chain reaction analysis. Hypertension 1994;24:538-548.
32. Ito M, Oliverio MI, Mannon PJ, et al: Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 1995;92:3521-3525.
33. Anderson NG, Mailer JL, Tonks NK, Sturgill TW: Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 1990;343:651-653.
34. Pulverer BJ, Kyriakis JM, Avruch J, et al: Phosphorylation of c-jun mediated by MAP kinases. Nature 1991; 353:670-674.
35. 2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase. Biochem Biophys Res Commun 1992;183: 206-211.
36. Liu YH, Yang XP, Sharov VG, et al: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997;99:1926-1935.
37. Nio Y, Matsubara H, Murasawa S, et al: Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 1995;95:46-54.
38. Franklin SS, Weber MA: Measuring hypertensive cardiovascular risk: the vascular overload concept. Am Heart J 1994;128:793-803.
39. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-1435.
40. Pfeffer MA, Braunwald E, Moye LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327: 669-677.
41. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
42. Zatz R, Dunn BR, Meyer TW, et al: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-1930.
43. Norman J, Badie-Dezfooly B, Nord EP, et al: EGF-induced mitogenesis in proximal tubular cells: potentiation by angiotensin H. Am J Physiol 1987;253:F299-309.
44. Nakamura T, Takahashi T, Fukui M, et al: Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J Am Soc Nephrol 1995;5:1492-1497.
45. Meyer TW, Anderson S, Rennke HG, Brenner BM: Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int 1987;31:752-759.
46. Anderson S, Diamond JR, Karnovsky MJ, Brenner BM: Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 1988;82:1757-1768.
47. Alhenc-Gelas F, Baussant T, Hubert C, et al: The angiotensin converting enzyme in the kidney. J Hypertens 1989;7(suppl):S9-13;discussion S14.
48. Ikemoto F, Song GB, Tominaga M, et al: Angiotensin-converting enzyme in the rat kidney. Activity, distribution, and response to angiotensin-converting enzyme inhibitors. Nephron 1990;55:3-9.
49. Ingelfinger JR, Dzau VJ: Molecular biology of renal injury: emphasis on the role of the renin-angiotensin system. J Am Soc Nephrol 1991;2:S9-20.
50. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study. N Engl J Med 1993;329:1456-1462.
51. Cattran DC, Greenwood C, Ritchie S: Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994;23:247-254.
52. Riser BL, Cortes P, Zhao X, et al: Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest 1992;90:1932-1943.
53. Arai M, Wada A, Isaka Y, et al: In vivo transfection of genes for renin and angiotensinogen into the glomerular cells induced phenotypic change of the mesangial cells and glomerular sclerosis. Biochem Biophys Res Commun 1995;206:525-532.
54. Ikoma M, Kawamura T, Kakinuma Y, et al: Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991;40:195-202.
55. Ichikawa I: Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int 1996;50:684-692.
56. Gansevoort RT, de Zeeuw D, de Jong PE: Long-term benefits of the antiproteinuric effect of angiotensinconverting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis 1993;22:202-206.
57. Williams JD, Coles GA: Proteinuria - a direct cause of renal morbidity? Kidney Int 1994;45:443-450.
58. D'Amico G, Ferrario F, Rastaldi MP: Tubulointerstitial damage in glomerular diseases: its role in the progression of renal damage. Am J Kidney Dis 1995;26:124-132.
59. Davies RW, Staprans I, Hutchison FN, Kaysen GA: Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 1990; 86:600-605.
60. Keilani T, Schlueter WA, Levin ML, Batlle DC: Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 1993;118:246-254.
61. Saunders E, Weir MR, Kong BW, et al: A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990;150:1707-1713.
62. van Paassen P, de Zeeuw D, Navis G, de Jong PE: Does the renin-angiotensin system determine the renal and systemic hemodynamic response to sodium in patients with essential hypertension? Hypertension 1996;27:202-208.
63. Moore TJ, Rich G, McKnight JA, et al: Salt sensitivity of hypertension and responses to angiotensin converting enzyme inhibition with benazepril. Am J Hypertens 1996;9:54-60.
64. Weir MR: Population characteristics and the modulation of the renin-angiotensin system in the treatment of hypertension. J Hum Hypertens 1997;11:17-21.
65. Weir MR, Gray JM, Paster R, Saunders E: Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 1995;26:124-130.
66. Weir MR, Saunders E: Renin status does not predict the anti-hypertensive response to angiotensin-converting enzyme inhibition in African-Americans. Trandolapril Multicenter Study Group. J Hum Hypertens 1998;12: 189-194.
67. Hollenberg NK, Fisher ND, Price DA: Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-392.
68. Gansevoort RT, de Zeeuw D, de Jong PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994;45:861-867.
69. Pitt B, Segal R, Martinez FA, et al: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752.